Literature DB >> 26955501

Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer.

Niels J Rupp1, Peter J Schüffler2, Qing Zhong1, Florian Falkner3, Markus Rechsteiner1, Jan H Rüschoff1, Christian Fankhauser1, Matthias Drach1, Remo Largo4, Mathias Tremp5, Cedric Poyet4, Tullio Sulser4, Glen Kristiansen6, Holger Moch1, Joachim Buhmann2, Michael Müntener7, Peter J Wild1.   

Abstract

BACKGROUND: Intratumoral hypoxia plays an important role with regard to tumor biology and susceptibility to radio- and chemotherapy. For further investigation of hypoxia-related changes, areas of certain hypoxia must be reliably detected within cancer tissues. Pimonidazole, a 2-nitroimindazole, accumulates in hypoxic tissue and can be easily visualized using immunohistochemistry.
MATERIALS AND METHODS: To improve detection of highly hypoxic versus normoxic areas in prostate cancer, immunoreactivity of pimonidazole and a combination of known hypoxia-related proteins was used to create computational oxygen supply maps of prostate cancer. Pimonidazole was intravenously administered before radical prostatectomy in n = 15 patients, using the da Vinci robot-assisted surgical system. Prostatectomy specimens were immediately transferred into buffered formaldehyde, fixed overnight, and completely embedded in paraffin. Pimonidazole accumulation and hypoxia-related protein expression were visualized by immunohistochemistry. Oxygen supply maps were created using the normalized information from pimonidazole and hypoxia-related proteins.
RESULTS: Based on pimonidazole staining and other hypoxia.related proteins (osteopontin, hypoxia-inducible factor 1-alpha, and glucose transporter member 1) oxygen supply maps in prostate cancer were created. Overall, oxygen supply maps consisting of information from all hypoxia-related proteins showed high correlation and mutual information to the golden standard of pimonidazole. Here, we describe an improved computer-based ex vivo model for an accurate detection of oxygen supply in human prostate cancer tissue.
CONCLUSIONS: This platform can be used for precise colocalization of novel candidate hypoxia-related proteins in a representative number of prostate cancer cases, and improve issues of single marker correlations. Furthermore, this study provides a source for further in situ tests and biochemical investigations.

Entities:  

Keywords:  Hypoxia; pimonidazole; prostate cancer

Year:  2016        PMID: 26955501      PMCID: PMC4763504          DOI: 10.4103/2153-3539.175376

Source DB:  PubMed          Journal:  J Pathol Inform


INTRODUCTION

Tumor hypoxia has been shown to drive malignant progression,[1] induce genetic instability,[2] and gene amplification,[3] as well as impair DNA repair mechanisms.[4] In particular, in prostate cancer, hypoxia was identified in vivo[5] and showed a significant association with advanced tumor stage[6] and aggressive disease.[7] Other studies showed an increased resistance to androgen deprivation and radio- and chemotherapy[8910] of tumors with large hypoxic regions. To create optical oxygen supply maps, we used a human ex vivo model, based on the compound pimonidazole.[11] Pimonidazole (hypoxyprobe™ -1; Chemicon International, Inc., Billerica, MA, USA), a 2-nitroimidazole, accumulates in vivo in hypoxic tissue (pO2 ≤ 10 mmHg at 37°C) and can be easily visualized in surgical specimens (ex vivo) by immunohistochemical analysis.[12] Pimonidazole is generally used in animal models, pimonidazole-based hypoxia labeling in human tissue samples is rarely performed because of ethical, pharmacological, and legal restrictions. To overcome these limitations, correlations between pimonidazole labeling and superimpositions with other known hypoxia-related proteins, including osteopontin (OPN),[1314] hypoxia-inducible factor 1-alpha (HIF1A),[1516] and glucose transporter member 1 (GLUT1),[1718] were investigated. Here, we describe a new method to reliably detect hypoxic tumor regions that does not employ invasive techniques, to further investigate hypoxia and hypoxia-related markers in prostatectomy specimens.

PROCEDURE

To verify that pimonidazole serves as a robust marker for hypoxia in prostate cancer cells, we incubated LNCaP cells (American Type Culture Collection, Manassas, VA, USA) under normoxic and hypoxic conditions, with or without pimonidazole. In accordance with the findings of previous studies,[1112] we confirmed pimonidazole as a direct marker for hypoxia. Immunocytochemical staining of pimonidazole revealed a clear positivity in LNCaP cells under hypoxic conditions while cells cultured under normoxic conditions were negative for pimonidazole [Figure 1a].
Figure 1

(a) In vitro validation of the anti-pimonidazole antibody by immunocytochemical staining using LNCaP prostate cancer cells. (b) Immunohistochemical staining for pimonidazole, osteopontin (O), hypoxia-inducible factor 1-alpha (H), and glucose transporter member 1 (G), scale bars 2 mm and 100 μm. (c) Generation of oxygen supply maps. (d) Dot-wise comparisons of both oxygen supply maps (OHG vs. P) in one representative case. (e and f) Box plots with Spearman correlation coefficients and mutual information comparing pimonidazole with osteopontin (O), hypoxia-inducible factor 1-alpha (H), glucose transporter member 1 (G), and combinatory overlays for 15 patients

(a) In vitro validation of the anti-pimonidazole antibody by immunocytochemical staining using LNCaP prostate cancer cells. (b) Immunohistochemical staining for pimonidazole, osteopontin (O), hypoxia-inducible factor 1-alpha (H), and glucose transporter member 1 (G), scale bars 2 mm and 100 μm. (c) Generation of oxygen supply maps. (d) Dot-wise comparisons of both oxygen supply maps (OHG vs. P) in one representative case. (e and f) Box plots with Spearman correlation coefficients and mutual information comparing pimonidazole with osteopontin (O), hypoxia-inducible factor 1-alpha (H), glucose transporter member 1 (G), and combinatory overlays for 15 patients After in vivo administration of pimonidazole, following radical prostatectomy, a total of 15 prostatectomy specimens [for cohort information see Supplementary Table 1] were subjected to immunohistochemical staining for pimonidazole, OPN, GLUT1, and HIF1A [Figure 1b]. Pimonidazole, GLUT1, and OPN showed a medium to strong cytoplasmic overall staining intensity, particularly of cancer tissues. Qualitative analysis of pimonidazole staining showed partial spatial overlapping of all hypoxia markers. A study in advanced head and neck squamous cell carcinoma described the rationale for colocalization of different hypoxia-related proteins with pimonidazole:[19] Individual hypoxia markers were higher expressed in pimonidazole-positive areas. However, the overall single correlation was poor. To this end, we targeted this issue by pooling all available information from hypoxia-related proteins to construct oxygen supply maps. Clinico-pathological data Click here for additional data file. The staining images for the known hypoxia-related proteins OPN (O), GLUT1 (G), and HIF1A (H) of each case were automatically color corrected, aligned, superimposed, and normalized for the generation of a pseudo-colored oxygen supply map [Figure 1c, OHG]. First, the original images were white-balanced to remove the grayish background. Second, the tissue regions were automatically identified and rotated, translated, cropped, and rescaled for rough alignment of the tissues to the middle slice. The background was then deleted to remove background artifacts which could disturb the following alignment process. Third, for pixel-wise matching and to conform to morphological changes of the tissues in consecutive slices, we incorporated a nonlinear SIFT flow algorithm[20] (see online methods for detailed description of all steps). Furthermore, an analogous oxygen supply map based on pimonidazole staining was created [Figure 1c, pimonidazole]. These maps were then normalized by histogram equalization and compared for each case using a dot-wise correlation of both images, which yielded high Spearman correlation coefficients [Figure 1e and Supplementary Figure 1a-o] and mutual information (MI) [Figure 1f]. MI between two images X and Y has been calculated as where P(x) is the probability of intensity x in the normalized histogram of X and P(x, y) is the probability of x and y in the normalized joint histogram of X and Y. All image processing steps were implemented in MATLAB 2014a, automatically performed and visually approved. A most simple combinatorial information of O, H, and G overlay maps were generated as the mean of individual intensity maps (more sophisticated combinations have not been considered in this study). Pimonidazole compared with an overlay of all three hypoxia markers (OHG) was highly correlative [Spearman correlation coefficient, r = 0.93, MI = 2.45; Figure 1d]. Comparison of pimonidazole with single markers (O, H, G) and combinatory overlays (OH, OG, HG) also showed high correlation coefficients [Figure 1e]. Only two cases revealed lower correlation coefficients [Supplementary Table 2]; B12-4671, B12-6064] because of crush artifacts. MI increases significantly in overlay images when combined with two or three markers [Figure 1f]. As previously shown,[11] scant correlations with microvessel density and pimonidazole could be observed in representative overlays of pimonidazole with CD34 immunoreactivity (n = 2, data not shown). (a-o) Spearman correlation matrices of O, H, G and combinations thereof. Oxygen supply maps based on pimonidazole staining and overlay images (OHG) for each of the 15 prostatectomy specimens are provided Click here for additional data file. Spearman correlation coefficients with pimonidazole Click here for additional data file.

CONCLUSION

Here, we introduce a computer-assisted approach to detect oxygen gradients in human prostate cancer tissues by colocalization of the expression of validated hypoxia-related markers compared to intravenously administered pimonidazole. The generated oxygen supply maps can be used to precisely colocalize potential hypoxia-related proteins in a quantitative and pictorial manner and will render compounds, such as pimonidazole, unnecessary in human patients.

Financial Support and Sponsorship

Nil.

Conflicts of Interest

There are no conflicts of interest.
  20 in total

1.  SIFT flow: dense correspondence across scenes and its applications.

Authors:  Ce Liu; Jenny Yuen; Antonio Torralba
Journal:  IEEE Trans Pattern Anal Mach Intell       Date:  2011-05       Impact factor: 6.226

2.  Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin.

Authors:  C P Sodhi; S A Phadke; D Batlle; A Sahai
Journal:  Am J Physiol Renal Physiol       Date:  2001-04

3.  Genetic instability induced by the tumor microenvironment.

Authors:  T Y Reynolds; S Rockwell; P M Glazer
Journal:  Cancer Res       Date:  1996-12-15       Impact factor: 12.701

Review 4.  Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target.

Authors:  Stina Häggström Rudolfsson; Anders Bergh
Journal:  Expert Opin Ther Targets       Date:  2009-02       Impact factor: 6.902

5.  Hypoxic regions exist in human prostate carcinoma.

Authors:  B Movsas; J D Chapman; E M Horwitz; W H Pinover; R E Greenberg; A L Hanlon; R Iyer; G E Hanks
Journal:  Urology       Date:  1999-01       Impact factor: 2.649

6.  Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells.

Authors:  S D Young; R S Marshall; R P Hill
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences.

Authors:  B L Ebert; J D Firth; P J Ratcliffe
Journal:  J Biol Chem       Date:  1995-12-08       Impact factor: 5.157

8.  Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4.

Authors:  Saskia E Rademakers; Jasper Lok; Albert J van der Kogel; Johan Bussink; Johannes H A M Kaanders
Journal:  BMC Cancer       Date:  2011-05-12       Impact factor: 4.430

9.  The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer.

Authors:  H B Ragnum; L Vlatkovic; A K Lie; K Axcrona; C H Julin; K M Frikstad; K H Hole; T Seierstad; H Lyng
Journal:  Br J Cancer       Date:  2014-12-02       Impact factor: 7.640

Review 10.  The impact of O2 availability on human cancer.

Authors:  Jessica A Bertout; Shetal A Patel; M Celeste Simon
Journal:  Nat Rev Cancer       Date:  2008-11-06       Impact factor: 60.716

View more
  5 in total

1.  Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor.

Authors:  Michael J Hwang; Kelly G Bryant; Jae H Seo; Qin Liu; Peter A Humphrey; Mary Ann C Melnick; Dario C Altieri; Marie E Robert
Journal:  Am J Pathol       Date:  2019-05-09       Impact factor: 4.307

2.  Histometabolic Tumor Imaging of Hypoxia in Oral Cancer: Clinicopathological Correlation for Prediction of an Aggressive Phenotype.

Authors:  Grégoire B Morand; Martina A Broglie; Paul Schumann; Martin W Huellner; Niels J Rupp
Journal:  Front Oncol       Date:  2020-08-27       Impact factor: 6.244

3.  Predictive Value of Pretherapeutic Maximum Standardized Uptake Value (Suvmax) In Laryngeal and Hypopharyngeal Cancer.

Authors:  Jonas Werner; Martin W Hüllner; Niels J Rupp; Alexander M Huber; Martina A Broglie; Gerhard F Huber; Grégoire B Morand
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

Review 4.  Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter.

Authors:  Tord Hompland; Christina Sæten Fjeldbo; Heidi Lyng
Journal:  Cancers (Basel)       Date:  2021-01-28       Impact factor: 6.639

5.  Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using 18F-fluoromisonidazole PET/CT: a pilot study.

Authors:  Stéphane Supiot; Caroline Rousseau; Mélanie Dore; Catherine Cheze-Le-Rest; Christine Kandel-Aznar; Vincent Potiron; Stéphane Guerif; François Paris; Ludovic Ferrer; Loïc Campion; Philippe Meingan; Gregory Delpon; Mathieu Hatt; Dimitris Visvikis
Journal:  Oncotarget       Date:  2018-01-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.